Advertisement

The Impact of Substance Abuse on Heart Failure Hospitalizations

      Abstract

      Background

      The burden of substance abuse among patients with heart failure and its association with subsequent emergency department visits and hospital admissions are poorly characterized.

      Methods

      We evaluated the medical records of patients with a diagnosis of heart failure treated at the University of California–San Diego from 2005 to 2016. We identified substance abuse via diagnosis codes or urine drug screens. We used Poisson regression to evaluate the incidence rate ratios (IRR) of substance abuse for emergency department visits or hospitalizations with a primary diagnosis of heart failure, adjusted for age, sex, race, medical insurance status, and medical diagnoses.

      Results

      We identified 11,268 patients with heart failure and 15,909 hospital encounters for heart failure over 49,712 person-years of follow-up. Substance abuse was diagnosed in 15.2% of patients. Disorders such as methamphetamine abuse (prevalence 5.2%, IRR 1.96, 95% confidence interval [CI] 1.85-2.07), opioid use and abuse (8.2%, IRR 1.54, 95% CI 1.47-1.61), and alcohol abuse (4.5%, IRR 1.51, 95% CI 1.42-1.60) were associated with a greater number of hospital encounters for heart failure, with associations that were comparable to diagnoses such as atrial fibrillation (37%, IRR 1.78, 95% CI 1.73-1.84), ischemic heart disease (24%, IRR 1.67, 95% CI 1.62-1.73), and chronic kidney disease (26%, IRR 1.57, 95% CI 1.51-1.62).

      Conclusions

      Although less prevalent than common medical comorbidities in patients with heart failure, substance-abuse disorders are significant sources of morbidity that are independently associated with emergency department visits and hospitalizations for heart failure. Greater recognition and treatment of substance abuse may improve outcomes among patients with heart failure.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Heidenreich P.A.
        • Albert N.M.
        • Allen L.A.
        • et al.
        Forecasting the Impact of heart failure in the united states: a poly statement from the american heart association.
        Circ Heart Fail. 2014; 6: 606-619
        • Huffman M.D.
        • Berry J.D.
        • Ning H.
        • et al.
        Lifetime Risk for heart failure among white and black americans: cardiovascular lifetime risk pooling project.
        J Am Coll Cardiol. 2013; 61: 1510-1517
        • Benjamin E.J.
        • Virani S.S.
        • Callaway C.W.
        • et al.
        Heart disease and stroke statistics—2018 update: a report from the American Heart Association.
        Circulation. 2018; 137: e67-e492
        • Jencks S.F.
        • Williams M.V.
        • Coleman E.A.
        Rehospitalizations among patients in the Medicare fee-for-service program.
        N Engl J Med. 2009; 360: 1418-1428
        • Bello N.A.
        • Claggett B.
        • Desai A.S.
        • et al.
        Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction.
        Circ Heart Fail. 2014; 7: 590-595
        • UNODC
        World drug report 2017: global overview of drug demand and supply.
        (Available at:)
        https://www.unodc.org/wdr2017/field/Booklet_2_HEALTH.pdf
        Date: 2017
        Date accessed: December 10, 2017
        • Abajobir A.A.
        • Abate K.H.
        • Abbafati C.
        • et al.
        Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
        Lancet. 2017; 390: 1260-1344
        • Havakuk O.
        • Rezkalla S.H.
        • Kloner R.A.
        The cardiovascular effects of cocaine.
        J Am Coll Cardiol. 2017; 70: 101-113
        • Paratz E.D.
        • Cunningham N.J.
        • MacIsaac A.I.
        The cardiac complications of methamphetamines.
        Heart Lung Circ. 2016; 25: 325-332
        • Mladěnka P.
        • Applová L.
        • Patočka J.
        • et al.
        Comprehensive review of cardiovascular toxicity of drugs and related agents.
        Med Res Rev. 2018; 38: 1332-1403
        • Mirijello A.
        • Tarli C.
        • Vassallo G.A.
        • et al.
        Alcoholic cardiomyopathy: what is known and what is not known.
        Eur J Intern Med. 2017; 43: 1-5
        • von Korff M.
        • Dublin S.
        • Walker R.L.
        • et al.
        The impact of opioid risk reduction initiatives on high-dose opioid prescribing for chronic opioid therapy patients.
        J Pain. 2016; 17: 101-110
        • Sliman S.
        • Waalen J.
        • Shaw D.
        Methamphetamine-associated congestive heart failure: increasing prevalence and relationship of clinical outcomes to continued use or abstinence.
        Cardiovasc Toxicol. 2016; 16: 381-389
        • Schürer S.
        • Klingel K.
        • Sandri M.
        • et al.
        Clinical characteristics, histopathological features, and clinical outcome of methamphetamine-associated cardiomyopathy.
        J Am Coll Cardiol HF. 2017; 5: 435-445
        • Won S.
        • Hong R.A.
        • Shohet R.V.
        • Seto T.B.
        • Parikh N.I.
        Methamphetamine-associated cardiomyopathy.
        Circ Cardiol. 2013; 36: 737-742
        • Mirkin K.A.
        • Enomoto L.M.
        • Caputo G.M.
        • Hollenbeak C.S.
        Risk factors for 30-day readmission in patients with congestive heart failure.
        Heart Lung. 2017; 46: 357-362
        • Vader J.M.
        • LaRue S.J.
        • Stevens S.R.
        • et al.
        Timing and causes of readmission after acute heart failure hospitalization-insights from the heart failure network trials.
        J Card Fail. 2016; 22: 875-883
        • Krumholz H.M.
        • Parent E.M.
        • Tu N.
        • et al.
        Readmission after hospitalization for congestive heart failure among Medicare beneficiaries.
        Arch Intern Med. 1997; 157: 99-104